NCT07024862View on ClinicalTrials.gov

Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy

Active, not recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

October 24, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Metastatic Non-small Cell Lung Cancer
Interventions
BIOLOGICAL

nivolumab + ipilimumab

First-line (1L) nivolumab + ipilimumab + 2 cycles of chemotherapy (NIC)

Trial Locations (1)

43017

Cardinal Health, Dublin

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY